With alterations in fibre type composition [72, 112] and satellite cell dysregulation evidenced in SMA muscle [23], an emerging alternative to predict drug candidates that target dysregulated SMA pathways in these muscle types would be single-cell (scRNA-Seq) and/or single nuclear RNA-Seq (snRNA-Seq) [111], which have already been useful tools in other muscular disorders such as DMD [113, 114]. The gene discussed is SMN1; the disease is Duchenne muscular dystrophy.